BS_A13BMEF5
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 4.270696452036794
- age_years
- 3.934
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.384
- CHOLESTEROL_HOMEOSTASIS+0.338
- PROTEIN_SECRETION+0.293
- INTERFERON_GAMMA_RESPONSE+0.266
- ADIPOGENESIS+0.254
- MYOGENESIS+0.246
- BILE_ACID_METABOLISM+0.200
- FATTY_ACID_METABOLISM+0.176
- UV_RESPONSE_DN+0.170
- NOTCH_SIGNALING+0.167
Top 10 suppressed
- MYC_TARGETS_V2-0.517
- E2F_TARGETS-0.495
- G2M_CHECKPOINT-0.448
- MYC_TARGETS_V1-0.424
- PANCREAS_BETA_CELLS-0.366
- ANGIOGENESIS-0.325
- UV_RESPONSE_UP-0.281
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.249
- TNFA_SIGNALING_VIA_NFKB-0.249
- HYPOXIA-0.226
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_42DY6WS7 | pilocytic astrocytoma | — | 0.848 |
| 2 | BS_55P8HPYD | pilocytic astrocytoma | — | 0.846 |
| 3 | BS_66ABA973 | pilocytic astrocytoma | — | 0.832 |
| 4 | BS_PEP9NZXN | low-grade glioma | — | 0.809 |
| 5 | BS_Z6BWR941 | low-grade glioma | — | 0.806 |
| 6 | BS_52DAPP1Y | low-grade glioma | — | 0.797 |
| 7 | C3N-00223 | — | cohortA1 | 0.788 |
| 8 | BS_H3FE3TH9 | pilocytic astrocytoma | — | 0.786 |
| 9 | f7683b51.cca9.4079.9e34.b9a4fdd27d85 | — | cohortA1 | 0.777 |
| 10 | BS_JKXA3FQC | low-grade glioma | — | 0.763 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.384 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.338 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.293 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.266 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.254 | Inavolisib | — uncovered |
| MYOGENESIS | 0.246 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.176 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.167 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.155 | Remibrutinib | — uncovered |
| PEROXISOME | 0.139 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.087 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.077 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.068 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.027 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.024 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.006 | Inavolisib | — uncovered |